Collectively, these findings suggest that DHQ ameliorates lipid metabolic disorders and inflammation in MASLD by modulating the HIF-1α/VEGF pathway, supporting its potential as a therapeutic candidate. This evidence concerns the gene VEGFA and metabolic dysfunction-associated steatotic liver disease.